 |
|
|
|
July 2000 Cover
|
|
Researchers from Glaxo Wellcome studied 79 HIV-1-positive patients to assess abacavir's ability in reducing viral loads. The patients were divided into four groups, receiving doses of abacavir ranging from 200 mg to
600 mg, and with some taking the drug by itself and others taking it in combination with zidovudine (AZT).
The researchers determined that abacavir given with zidovudine is more effective in lowering HIV-1 load than abacavir alone. The study also showed, however, that when antiretroviral therapy is stopped,
viral load rebounds quickly.
Editor's Note: from Reuters Health Info Services
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
